ESR1 and triple-negative breast carcinoma: The first project focused on predicting response to carboplatin/docetaxel therapy in triple-negative breast cancer (TNBC), while the new project is focused on predicting response to endocrine therapy (ET) in advanced estrogen receptor-positive (ER+) BCa.